FILE - The Biogen Inc., headquarters is pictured on March 11, 2020, in Cambridge, Mass. Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple of years ago. The drugmaker said Wednesday, Jan. 31, 2024 that it will end a study of the drug needed for full approval from the Food and Drug Administration, and it will stop sales of the drug.(AP Photo/Steven Senne, File)
Featured Photo Galleries
